Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What is the current market size of the pernicious anemia diagnosis and treatment industry, and what growth rate is it expected to achieve?
The pernicious anemia diagnosis and treatment market size has grown strongly in recent years. It will grow from $1.42 billion in 2024 to $1.52 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth in the historic period can be attributed to increasing awareness of vitamin B12 deficiency, growing prevalence of autoimmune disorders, rise in geriatric population, increased physician education on anemia, and availability of oral and injectable vitamin B12.
The pernicious anemia diagnosis and treatment market size is expected to see strong growth in the next few years. It will grow to $1.97 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to the expansion of telemedicine services, the growing demand for early diagnosis, the rising focus on personalized medicine, government screening initiatives, and rising patient preference for non-invasive treatments. Major trends in the forecast period include the development of long-acting vitamin B12 formulations, growing use of home-based diagnostic kits, integration of artificial intelligence (AI) in anemia detection, rise in digital health monitoring tools, and advancements in diagnostic technologies.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24360&type=smp
What are the major drivers contributing to the growth of the pernicious anemia diagnosis and treatment market?
The rising prevalence of vitamin B12 deficiency is expected to drive growth in the pernicious anemia diagnosis and treatment market going forward. Vitamin B12 deficiency occurs when the body lacks enough of the vitamin to produce adequate red blood cells, leading to symptoms such as fatigue, weakness, and neurological issues. Vitamin B12 deficiency is rising due to the increasing adoption of plant-based diets, which often lack sufficient natural sources of B12 and can lead to inadequate intake without proper supplementation. Vitamin B12 deficiency supports pernicious anemia diagnosis and treatment as low B12 levels directly impair red blood cell production, guiding doctors to administer B12 supplementation as a primary and effective treatment strategy. For instance, in February 2023, according to a report published by the National Health Service (NHS), a UK-based government health organization, both vitamin B12 and folate deficiencies are more prevalent in older adults, affecting roughly 1 in 10 individuals 75 years of age or older and 1 in 20 of those 65 to 74 years of age. Therefore, the rising prevalence of vitamin B12 deficiency is driving growth in the pernicious anemia diagnosis and treatment market.
What are the major market segments driving the growth of the pernicious anemia diagnosis and treatment industry?
The pernicious anemia diagnosis and treatment market covered in this report is segmented –
1) By Type: Complete Blood Count Test, Vitamin B12 Deficiency test, Intrinsic Factor Deficiency Test
2) By Treatment: Vitamin B12 Injections, Vitamin B12 Pills, Spray
3) By Route Of Administration: Injection, Oral, Intranasal
4) By End-User: Hospitals, Clinics, Diagnostic Centres, Other End-users
Subsegments:
1) By Complete Blood Count (CBC) Test: Red Blood Cell Count, Hemoglobin Concentration, Hematocrit Levels, Mean Corpuscular Volume (MCV), White Blood Cell Count, Platelet Count
2) By Vitamin B12 Deficiency Test: Serum Vitamin B12 Test, Methylmalonic Acid (MMA) Test, Homocysteine Test, Holotranscobalamin (Active B12) Test
3) By Intrinsic Factor Deficiency Test: Intrinsic Factor Antibody Test, Parietal Cell Antibody Test, Schilling Test, Gastrin Level Test
View The Full Market Report:
What evolving trends are creating new opportunities in the pernicious anemia diagnosis and treatment market?
Major companies operating in the pernicious anemia diagnosis and treatment market are focusing on developing innovative solutions, such as vitamin B12 maintenance therapy solutions, to improve patient adherence and long-term disease management. Vitamin B12 maintenance therapy solutions involve regular, ongoing supplementation through oral tablets, injections, or nasal sprays to sustain adequate B12 levels and prevent recurrence of deficiency-related symptoms. For instance, in February 2024, Lupin Pharmaceuticals Inc., an India-based pharmaceutical company, launched cyanocobalamin nasal spray, 500 mcg/spray, a non-invasive alternative for vitamin B12 supplementation. This nasal spray provides a convenient and effective method for patients with pernicious anemia who struggle with oral vitamin B12 forms. It helps improve B12 absorption and supports the management of vitamin B12 deficiency, ultimately enhancing patient compliance and treatment outcomes.
Who are the key market players contributing to the growth of the pernicious anemia diagnosis and treatment industry?
Major companies operating in the pernicious anemia diagnosis and treatment market are Pfizer Inc., F.Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb Company, Thermo Fisher Scientific Inc., GSK plc, Takeda Pharmaceutical Company Limited, Lupin Limited, Eli Lilly and Company, Amgen Inc., DSM Nutritional Products AG, Bio-Rad Laboratories Inc., CSL Vifor Pharma, Daiichi Sankyo Co. Ltd., Par Pharmaceutical Companies Inc., AdvaCare Pharma, Monobind Inc.
Which regions are leading the growth of the pernicious anemia diagnosis and treatment market globally?
North America was the largest region in the pernicious anemia diagnosis and treatment market in 2024. The regions covered in the pernicious anemia diagnosis and treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Pernicious Anemia Diagnosis And Treatment Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/customise?id=24360&type=smp
Need Customized Data On Pernicious Anemia Diagnosis And Treatment Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24360&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
